ANTIFUNGAL SUSCEPTIBILITY OF CRYPTOCOCCUS NEOFORMANS ISOLATES FROM FUNGAL MENINGITIS IN AIDS PATIENTS IN INDIA

Authors

  • Rajani Sharma Department of Microbiology, PGIMER & Dr. RML Hospital, New Delhi
  • Nandini Duggal Department of Microbiology, PGIMER & Dr. RML Hospital, New Delhi
  • Shalini Malhotra Department of Microbiology, PGIMER & Dr. RML Hospital, New Delhi
  • Dinesh Shrivastava Department of Medicine PGIMER & Dr. RML Hospital, New Delhi
  • Charoo Hans Department of Microbiology, PGIMER & Dr. RML Hospital, New Delhi

Keywords:

Antifungal susceptibility, Cryptococcal meningitis, HIV, India, MICs

Abstract

Objectives: This study was undertaken to determine the antifungal susceptibility of fifteen cryptococcal isolates from cerebrospinal fluid (CSF) of HIV seropositive patients with cryptococcal meningitis.

Methods: Antifungal susceptibility testing of the isolates was done by CLSI M27 A-3 methodology for amphotericin B, fluconazole, voriconazole, itraconazole and 5-flucytosine.

Results: Our study demonstrates no evidence of resistance among clinical isolates of Cryptococcus neoformans for any of the above mentioned antifungal drugs. Only two isolates showed slightly higher minimum inhibitory concentration (MIC) to 5-flucytosine (8 µg/ml).

Conclusion: Routine In vitro antifungal susceptibility for cryptococcal isolates is important, in order to obtain a baseline data and to predict any shift in the susceptibility patterns in the Indian population.

Downloads

Download data is not yet available.

References

years after the discovery of Cryptococcus neoformans. J Clin Microbiol Rev 1995;8(4):515-48.

Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States:1992 to 1994 and 1996 to 1998. J Antimicrob Agents Chemother 2001;45(11):3065-9.

Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. J AIDS (London, England) 2009;23(4):525-30.

Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy:the role of fluconazole resistance and immune reconstitution. Clinical infectious diseases:an official publication of the Infectious. J Diseases Society of America 2006;43(8):1069-73.

Wayne PA. Clinical and Laboratory Standards Institute2008. M27-A3 p.

Shankar SK, Mahadevan A, Satishchandra P, Kumar RU, Yasha TC, Santosh V, et al. Neuropathology of HIV/AIDS with an overview of the Indian scene. Indian J of Medical Res 2005;121(4):468-88.

Bicanic T, Harrison TS. Cryptococcal meningitis. J Br Med Bull 2005;72:99-118.

Aller AI, Claro R, Castro C, Serrano C, Colom MF, Martín-Mazuelos E. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain. J Chemotherapy 2007;53(4):300-5.

Chandenier J, Adou-Bryn KD, Douchet C, Sar B, Kombila M, Swinne D, et al. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. European journal of clinical microbiology & infectious diseases:official publication. J European Society of Clinical Microbiology 2004;23(6):506-8.

Pfaller MA, Zhang J, Messer SA, Brandt ME, Hajjeh RA, Jessup CJ, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. J Antimicrob Agents Chemother 1999;43(1):169-71.

Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of america. Clinical infectious diseases:an official publication of the Infectious. J Diseases Society of America 2010;50(3):291-322.

Klepser ME, Pfaller MA. Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994. J Clin Microbiol 1998;36(12):3653-6.

Archibald LK, Tuohy MJ, Wilson DA, Nwanyanwu O, Kazembe PN, Tansuphasawadikul S, et al. Antifungal susceptibilities of Cryptococcus neoformans. J Emerg Infect Dis 2004;10(1):143-5.

Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India:a need for care. J of Antimicrobial Chemotherapy 2003;52(4):683-6.

Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, et al. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol 2011;60(Pt 7):961-7.

Casadevall A, Spitzer ED, Webb D, Rinaldi MG. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole1993. 1383-6 p.

Paugam A, Dupouy-Camet J, Blanche P, Gangneux JP, Tourte-Schaefer C, Sicard D. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clinical infectious diseases:an official publication of the Infectious. J Diseases Society of America 1994;19(5):975-6.

Published

01-07-2014

How to Cite

Sharma, R., N. Duggal, S. Malhotra, D. Shrivastava, and C. Hans. “ANTIFUNGAL SUSCEPTIBILITY OF CRYPTOCOCCUS NEOFORMANS ISOLATES FROM FUNGAL MENINGITIS IN AIDS PATIENTS IN INDIA”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 7, July 2014, pp. 584-6, https://www.innovareacademics.in/journals/index.php/ijpps/article/view/2022.

Issue

Section

Original Article(s)